@article{1d0bf68a8d5d49c0b492928dbfe99c2e,
title = "Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium",
keywords = "Metastatic breast cancer, Bevacizumab, Cost-effectiveness analysis, Real-world, Trial based, Cost-benefit analysis, RANDOMIZED PHASE-III, 1ST-LINE TREATMENT, PLUS DOCETAXEL, PACLITAXEL, WOMEN",
author = "{van Kampen}, {R. J. W.} and Ramaekers, {B. L. T.} and Lobbezoo, {D. J. A.} and {de Boer}, M. and Dercksen, {M. W.} and {van den Berkmortel}, F. and Smilde, {T. J.} and {van de Wouw}, {A. J.} and Peters, {F. P. J.} and {van Riel}, {J. M. G.} and Peters, {N. A. J. B.} and Tjan-Heijnen, {V. C. G.} and Joore, {M. A.}",
year = "2017",
month = jul,
doi = "10.1016/j.ejca.2017.01.027",
language = "English",
volume = "79",
pages = "238--246",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",
}